Live tape
Top 8, mentions 7d7,587META2,272 mentions▲ +0.06GOOGL1,514 mentions▲ +0.02NVDA815 mentions▲ +0.09MUSE667 mentions▲ +0.07MSFT611 mentions▲ +0.06SPY579 mentions▲ +0.05QQQ567 mentions▲ +0.08TSLA562 mentions▲ +0.06

Equity · Healthcare

ACAD

ACADIA Pharmaceuticals Inc. · NasdaqGS

$20.69 −6.78% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Sep 25, 2026
Price · Chart
Our own end-of-day closes 62 sessions
$35 $20 30 Jun 25 Sep

The line runs $25.30 on 30 June through $20.69 on 25 September, on a scale from $20 to $35. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of ACAD over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 62 sessions over that window: $25.30 on 30 June 2026 through $20.69 on 25 September 2026.

Market cap $3.6B
P/E (TTM) 9.3
52-week range $20 – $30.58
Avg volume 117.0K

Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Sep 25, 2026

ACAD insider trades

SEC Form 4 · last 90 days · newest reported trade 6 Aug 2026
Open-market buys 0
Open-market sells 3
Net sold $1.02M
Non-trade filings 3
Date Insider Type Shares Value
06 Aug 2026 Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER Sell 14,292 $418K
05 Aug 2026 Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER Sell 5,849 $170K
30 Jul 2026 Thompson Elizabeth H.Z. EVP, Head of Research & Dev Sell 16,558 $433K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
06 Aug 2026 Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER Option exercise 14,292 $255K
05 Aug 2026 Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER Option exercise 5,849 $104K
29 Jul 2026 Thompson Elizabeth H.Z. EVP, Head of Research & Dev Option exercise 32,272

ACAD reported financials

SEC EDGAR XBRL

ACAD reported revenue of $1.1B for the fiscal year ended 31 Dec 2025. Net income over the same period was $391.0M.

Figure Reported Period
Revenue $1.1B 31 Dec 2025 fiscal year
Net income $391.0M 31 Dec 2025 fiscal year
Diluted EPS $2.30 31 Dec 2025 fiscal year
Total assets $1.7B 30 Jun 2026 at period end
Total equity $1.3B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

ACAD earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $0.18 —
31 Mar 2026 Q1 2026 $0.02 —
31 Dec 2025 FY 2025 $2.30 —
30 Sep 2025 Q3 2025 $0.42 —
30 Jun 2025 Q2 2025 $0.16 —
31 Mar 2025 Q1 2025 $0.11 —
31 Dec 2024 FY 2024 $1.36 —
30 Sep 2024 Q3 2024 $0.20 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

ACAD institutional holders

SEC Form 13F

13 of the 45 institutional funds we track reported a ACAD position for the quarter ended 30 Jun 2026 — a combined $1.4B; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Baker Bros. Advisors Held (±25%) +0.0% shares 42,912,904 $1.1B
Point72 Asset Management Held (±25%) −5.6% shares 2,433,168 $61.6M
Citadel Advisors Added +250.4% shares 2,182,177 $55.2M
Marshall Wace Added +2,216.5% shares 1,764,838 $44.7M
D. E. Shaw & Co. Added +132.6% shares 1,697,937 $43.0M
Renaissance Technologies Trimmed −25.6% shares 1,282,596 $32.4M
Two Sigma Investments Held (±25%) +19.6% shares 926,992 $23.5M
Fisher Asset Management Held (±25%) −4.6% shares 699,230 $17.7M
Millennium Management Held (±25%) −16.4% shares 589,924 $14.9M
AQR Capital Management Held (±25%) −1.0% shares 522,749 $13.2M

Showing the 10 largest of 13 reported positions. The figures above count all of them.

Source: SEC EDGAR 13F filings